Overview

Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rectal Cancer (TORCH-LE)

Status:
RECRUITING

Trial end date:
2029-12-30

Target enrollment:

Participant gender:

Summary

This is a single arm phase II study to explore the 3y LRFS and safety for high-risk early rectal cancer after local excision with short-course radiotherapy and chemo-immunotherapy.

Phase:

PHASE2

Details

Lead Sponsor:

Fudan University

Treatments:

Capecitabine
Oxaliplatin
Radiation
spartalizumab
toripalimab